Carolina F M G Pimentel1, Zhenghui G Jiang2, Takeshi Otsubo2, Linda Feldbrügge2, Tracy L Challies3, Imad Nasser3, Simon Robson2, Nezam Afdhal2, Michelle Lai2. 1. Division of Gastroenterology/Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 4 A, Boston, MA, 02215, USA. carolinapimentel.gastro@gmail.com. 2. Division of Gastroenterology/Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 4 A, Boston, MA, 02215, USA. 3. Division of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD) affects 15-40% of the general population; 10-20% of those patients have a more severe form of the disease known as nonalcoholic steatohepatitis (NASH). Cytokeratin-18 (CK18), released during apoptosis and one of the most studied biomarkers in NASH, can be measured by a number of commercially available kits. We compared serum measurements of the CK18 M30 from two different kits using the same cohort to evaluate the reliability between two test kits. METHODS: We measured serum levels of CK18 M30 from 185 patients with biopsy-proven NAFLD from a single center from 2009 to 2015, using two different ELISA kits, Test 1 (T1) and Test 2 (T2). Advanced fibrosis was defined as fibrosis stages 3-4 and NASH defined by NAS score ≥ 5. RESULTS: Mean age was 50.2 years (SD 12.6), 61.1% male and 87% White; 49.6% had NASH and 32.2% advanced fibrosis. There was no significant correlation between measurements from the two kits (p = 0.86, r = 0.01). While T2 predicted NASH and advanced fibrosis, T1 did not. The area under ROC curve for the prediction of NASH was 0.631 for T2 versus 0.500 for T1. CONCLUSIONS: Measurements from two different CK18 M30 test kits did not correlate with each other. One kit showed statistically significantly higher levels of CK18 M30 in patients with advanced fibrosis and NASH, while the other kit did not. With the increasing use of CK18 as a biomarker in NASH, it is important to standardize the different kits as it could greatly bias the results.
BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD) affects 15-40% of the general population; 10-20% of those patients have a more severe form of the disease known as nonalcoholic steatohepatitis (NASH). Cytokeratin-18 (CK18), released during apoptosis and one of the most studied biomarkers in NASH, can be measured by a number of commercially available kits. We compared serum measurements of the CK18 M30 from two different kits using the same cohort to evaluate the reliability between two test kits. METHODS: We measured serum levels of CK18 M30 from 185 patients with biopsy-proven NAFLD from a single center from 2009 to 2015, using two different ELISA kits, Test 1 (T1) and Test 2 (T2). Advanced fibrosis was defined as fibrosis stages 3-4 and NASH defined by NAS score ≥ 5. RESULTS: Mean age was 50.2 years (SD 12.6), 61.1% male and 87% White; 49.6% had NASH and 32.2% advanced fibrosis. There was no significant correlation between measurements from the two kits (p = 0.86, r = 0.01). While T2 predicted NASH and advanced fibrosis, T1 did not. The area under ROC curve for the prediction of NASH was 0.631 for T2 versus 0.500 for T1. CONCLUSIONS: Measurements from two different CK18 M30 test kits did not correlate with each other. One kit showed statistically significantly higher levels of CK18 M30 in patients with advanced fibrosis and NASH, while the other kit did not. With the increasing use of CK18 as a biomarker in NASH, it is important to standardize the different kits as it could greatly bias the results.
Authors: Gero Kramer; Hamdiye Erdal; Helena J M M Mertens; Marius Nap; Julian Mauermann; Georg Steiner; Michael Marberger; Kenneth Bivén; Maria C Shoshan; Stig Linder Journal: Cancer Res Date: 2004-03-01 Impact factor: 12.701
Authors: Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough Journal: Hepatology Date: 2009-10 Impact factor: 17.425
Authors: Zhenghui G Jiang; Elliot B Tapper; Margery A Connelly; Carolina F M G Pimentel; Linda Feldbrügge; Misung Kim; Sarah Krawczyk; Nezam Afdhal; Simon C Robson; Mark A Herman; James D Otvos; Kenneth J Mukamal; Michelle Lai Journal: Liver Int Date: 2016-02-24 Impact factor: 5.828
Authors: Nicole E Rich; Stefany Oji; Arjmand R Mufti; Jeffrey D Browning; Neehar D Parikh; Mobolaji Odewole; Helen Mayo; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2017-09-29 Impact factor: 11.382
Authors: Rebeca Mayo; Javier Crespo; Ibon Martínez-Arranz; Jesus M Banales; Mayte Arias; Itziar Mincholé; Rocío Aller de la Fuente; Raúl Jimenez-Agüero; Cristina Alonso; Daniel A de Luis; Libor Vitek; Jan Stritesky; Joan Caballería; Manuel Romero-Gómez; Antonio Martín-Duce; Jose Maria Mugüerza Huguet; José Ignacio Busteros-Moraza; Michael O Idowu; Azucena Castro; M Luz Martínez-Chantar; Pablo Ortiz; Radan Bruha; Shelly C Lu; Pierre Bedossa; Mazen Noureddin; Arun J Sanyal; José M Mato Journal: Hepatol Commun Date: 2018-05-04